Patients who meet electrodiagnostic criteria for CIDP rarely present with a sensory predominant DSP phenotype. Issue 6 (8th April 2021)

• Record Type: Journal Article
• Authors: Davalos, Long; London, Zachary N.; Stino, Amro M.; Gallagher, Gary W.; Callaghan, Brian C.; Wieland, Clare M.; Nowacek, Dustin G.
• Is Part Of: Muscle & nerve. Volume 63:Issue 6(2021)
• Page Start: 881
• Page End: 884
• Publication Date: 2021-04-08
• Subjects: acquired demyelinating neuropathy -- chronic inflammatory demyelinating polyneuropathy -- distal symmetric polyneuropathy -- electrodiagnostic testing; Neuromuscular diseases -- Periodicals; Muscles -- Periodicals; Nerves -- Periodicals; 616.74
• DOI: 10.1002/mus.27235
• Languages: English
• ISSNs: 0148-639X

Abstract

Abstract: Introduction: It is unknown how often patients with electrodiagnostic evidence of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a potentially treatable condition, present with a distal symmetric polyneuropathy (DSP) phenotype. Methods: We reviewed the records of patients who presented to our electrodiagnostic laboratory between January 1, 2011, to December 31, 2019, and fulfilled electrodiagnostic criteria for CIDP to identify those who presented with a sensory predominant DSP phenotype. Results: One hundred sixty‐two patients had a chronic acquired demyelinating neuropathy, of whom 138 met criteria for typical or atypical CIDP. Nine of these patients presented with a sensory predominant DSP phenotype, among whom six were eventually diagnosed with distal acquired demyelinating symmetric (DADS) neuropathy; one with Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes (POEMS) syndrome; and two with idiopathic DSP. The prevalence of acquired chronic demyelinating neuropathies among all patients presenting with a DSP phenotype was estimated to be 0.34%. Discussion: Patients who meet electrodiagnostic criteria for CIDP rarely present with a sensory predominant DSP phenotype, and electrodiagnostic testing rarely identifies treatable demyelinating neuropathies in patients who present with a DSP phenotype.